Renal Cell Carcinoma Drug Gains Approval by Physicians Weekly | Apr 16, 2012 | 0 comments Advertisement FacebookTwitterLinkedinThe FDA has approved axitinib (Inlyta, Pfizer) for the treatment of advanced renal cell carcinoma (RCC). The drug is given twice daily and indicated for patients who have not responded to other RCC cancer medications. Source: FDA. Submit a Comment Cancel reply Your email address will not be published. Required fields are marked *Comment Name * Email * Website Please enter an answer in digits:17 − 3 =